Live, attenuated respiratory syncytial virus
AssigneeMerck Sharp & Dohme Corp.
InventorsMary K. Yagodich, Michael P. Citron, Daniel J. Distefano, Daniel L. Krah, Xiaoping Liang
Life of this patent
Estimating the term…
Abstract
The present invention features live, attenuated respiratory syncytial viruses (RSV) useful as vaccines against RSV infection and/or the development of severe RSV-associated illnesses. The disclosed viruses are attenuated to the extent of being nonpathogenic when administered to a subject but substantially retain the antigenic and immunogenic properties of wild-type RSV.
Claims11
A live, attenuated respiratory syncytial virus (RSV) comprising a viral genome, wherein the viral genome encodes proteins that comprise a glutamic acid at position 204 of the protein encoded by the G gene;
- a glutamic acid at position 205 of the protein encoded by the G gene;
- an alanine at position 211 of the protein encoded by the G gene;
- a glutamic acid at position 213 of the protein encoded by the G gene;
- a glycine at position 221 of the protein encoded by the G gene;
- a glycine at position 223 of the protein encoded by the G gene;
- a glycine at position 232 of the protein encoded by the G gene;
- a glycine at position 486 of the protein encoded by the F gene;
- and an alanine at position 148 of the protein encoded by the L gene.
Dependencies are inferred from the claim text.